On my journey in search of a new Revenio, in a country where vague Finland-Swedish was spoken and which was ruled by Carl XVI Gustaf, I came across a company called Acarix. And I’m not comparing this to be a new Revenio.
For the diagnosis of coronary artery disease, a common basic examination is still the stress test, which is expensive, difficult to arrange, and time-consuming. Another common option is CT imaging, but this is also expensive and difficult to arrange.
Acarix has invented a money and time-saving solution for this, for the screening of first-level patients, i.e., with the purpose of determining who should be sent for further examinations and who should not.
The device already has all the necessary approvals in America as well; a De Novo application from the FDA was approved at the end of last year.
https://acarix.com/blog/2020/11/25/mar-acarix-receives-us-market-approval-for-the-cadscor-system/
Currently, various reimbursement decisions are awaited from England, Germany, and America. During the autumn, some progress should be heard from at least some of these.
New positive research results have been published recently, and the news flow has generally been positive.
Revenue is small, but the company seems to have good momentum and approvals in order. The next trigger for the stock is indeed those reimbursement decisions, after which sales should really take off.
The company has a Razor/Razorblade style business model, i.e., selling the device and, as continuous sales, disposable hygienic attachment parts.
The company’s cash situation is somewhat poor; a new funding round is likely to come later this year.
Redeye is also turning positive on this company, and the company is now under review according to their pages, meaning an update is coming soon: "To acknowledge rising conviction in the case and the progress made by the company since our coverage initiation, our assessment of Acarix is currently under evaluation. We look forward to returning with a research update and an updated fair value range for Acarix.”
Q2 report: https://acarix.com/wp-content/uploads/2021/05/acarixq2eng2021.pdf
Do your own thorough research on the stock; you may lose your invested capital. This is not a buy recommendation for the stock.
